Page 49 - Read Online

Page 10 of 11 Minami et al. Hepatoma Res 2020;6:46 I http://dx.doi.org/10.20517/2394-5079.2020.32

carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
4. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, et al. JSH consensus-based clinical practice guidelines for the management of
hepatocellular carcinoma: 2014 update by the liver Cancer study Group of Japan. Liver Cancer 2014;3:458-68.
5. Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, et al. 2017 version of LI-RADS for CT and MR imaging: an update.
Radiographics 2017;37:1994-2017.
6. de Jong N, Emmer M, van Wamel A, Versluis M. Ultrasonic characterization of ultrasound contrast agents. Med Biol Eng Comput
2009;47:861-73.
7. Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, et al. The AFSUMB consensus statements and recommendations for the clinical practice
of contrast-enhanced ultrasound using sonazoid. Ultrasonography 2020;39:191-220.
8. Wilson SR, Lyshchik A, Piscaglia F, Cosgrove D, Jang HJ, et al. CEUS LI-RADS: algorithm, implementation, and key differences from
CT/MRI. Abdom Radiol (NY) 2018;43:127-42.
9. Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer 2018;7:134-47.
10. Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J
Gastroenterol 2011;17:4952-9.
11. Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Ultrasound diagnostic criteria for hepatic
tumors. J Med Ultrason 2014;41:113-23.
12. Chung YE, Kim KW. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography 2015;34:3-
18.
13. Eckersley RJ, Chin CT, Burns PN. Optimising phase and amplitude modulation schemes for imaging microbubble contrast agents at low
acoustic power. Ultrasound Med Biol 2005;31:213-9.
14. Needles A, Arditi M, Rognin NG, Mehi J, Coulthard T, et al. Nonlinear contrast imaging with an array-based micro-ultrasound system.
Ultrasound Med Biol 2010;36:2097-106.
15. Gong P, Song P, Chen S. Improved contrast-enhanced ultrasound imaging with multiplane-wave imaging. IEEE Trans Ultrason
Ferroelectr Freq Control 2018;65:178-87.
16. Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, et al. Contrast-enhanced tissue harmonic imaging versus phase inversion
harmonic sonographic imaging for the delineation of hepatocellular carcinomas. Oncology 2017;92:29-34.
17. Tanaka H. Current role of ultrasound in the diagnosis of hepatocellular carcinoma. J Med Ultrason (2001) 2020;47:239-55.
18. Niu Y, Huang T, Lian F, Li F. Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma: a meta-analysis and
meta-regression analysis. Tumour Biol 2013;34:3667-74.
19. Kan M, Hiraoka A, Uehara T, Hidaka S, Ichiryu M, et al. Evaluation of contrast-enhanced ultrasonography using perfluorobutane
(Sonazoid(®)) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography. Oncol Lett
2010;1:485-8.
20. Zheng RQ, Zhou P, Kudo M. Hepatocellular carcinoma with nodule-in-nodule appearance: demonstration by contrast-enhanced coded
phase inversion harmonic imaging. Intervirology 2004;47:184-90.
21. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with
histologic differentiation. Radiology 2007;244:898-906.
22. Jang JY, Kim MY, Jeong SW, Kim TY, Kim SU, et al. Current consensus and guidelines of contrast enhanced ultrasound for the
characterization of focal liver lesions. Clin Mol Hepatol 2013;19:1-16.
23. Hatanaka K, Minami Y, Kudo M, Inoue T, Chung H, et al. The gross classification of hepatocellular carcinoma: usefulness of contrast-
enhanced US. J Clin Ultrasound 2014;42:1-8.
24. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid
in the management of hepatocellular carcinoma. Oncology 2010;78:40-5.
25. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, et al. World Federation for Ultrasound in Medicine; European Federation of
Societies for Ultrasound. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver
- update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.
Ultrasound Med Biol 2013;39:187-210.
26. Kudo M. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 2011;81:73-85.
27. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, et al. B-Mode ultrasonography versus contrast-enhanced ultrasonography for
surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer 2019;8:271-80.
28. Yang HK, Burns PN, Jang HJ, Kono Y, Khalili K, et al. Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the
importance of washout. Ultrasonography 2019;38:289-301.
29. Liu GJ, Wang W, Lu MD, Xie XY, Xu HX, et al. Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and
intrahepatic cholangiocarcinoma. Liver Cancer 2015;4:241-52.
30. Dietrich CF, Mertens JC, Braden B, Schuessler G, Ott M, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas.
Hepatology 2007;45:1139-45.
31. Kong WT, Wang WP, Cai H, Huang BJ, Ding H, et al. The analysis of enhancement pattern of hepatic inflammatory pseudotumor on
contrast-enhanced ultrasound. Abdom Imaging 2014;39:168-74.
32. Friedrich-Rust M, Klopffleisch T, Nierhoff J, Herrmann E, Vermehren J, et al. Contrast-enhanced ultrasound for the differentiation of
benign and malignant focal liver lesions: a meta-analysis. Liver Int 2013;33:739-55.
33. Xie L, Guang Y, Ding H, Cai A, Huang Y. Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic